生物医药公司COMPASS Pathways plc宣布，美国食品药品监督管理局（FDA）已正式批准其新药申请（NDA）的滚动审评请求，同时授予专员国家优先审评券。这一重要进展将显著加速该公司创新疗法的审评进程。
滚动审评机制允许制药企业分阶段提交NDA资料，而非一次性提交完整申请材料，有助于FDA更早介入审评流程。国家优先审评券的授予进一步体现了该疗法在解决未满足医疗需求方面的重要价值，将为后续审评提供优先通道。
此次监管突破标志着COMPASS Pathways在精神健康领域创新药物研发取得实质性进展，为公司核心产品的商业化奠定重要基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.